MedPath

An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction

Phase 2
Recruiting
Conditions
Tobacco Use Disorder
Interventions
Drug: Placebo oral capsule
Registration Number
NCT03713424
Lead Sponsor
University of Missouri-Columbia
Brief Summary

This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo oral capsule4-day, twice-daily oral capsule administration
ClavClavulanic Acid4-day 125 bid oral capsule administration
Primary Outcome Measures
NameTimeMethod
Cigarette Smoking5 days

Biochemical smoking assessment (breath carbon monoxide) at each study visit.

Self Reported Side Effects5 Days

Number of reported side effects

Secondary Outcome Measures
NameTimeMethod
Magnitude of change in BOLD fMRI brain response to smoking related images4 days

Measure the effects of Clavulanic Acid on fMRI BOLD response to images (change from baseline to end of study) while participants undergo functional magnetic resonance imaging

Magnitude of change in resting-stated fMRI brain connectivity4 days

Measure the effects of Clavulanic Acid on resting-state functional connectivity (change from baseline to end of study) while participants undergo functional magnetic resonance imaging.

Trial Locations

Locations (1)

University of Missouri - Columbia

🇺🇸

Columbia, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath